Balyasny Asset Management’s TriSalus Life Sciences TLSI Stock Holding History

Balyasny Asset Management’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,804	Closed	-$59.6K	–	3347
2025 Q1	$59.6K	Buy	+10,804	New	+$57.5K	﹤0.01%	2705
2022 Q4	–	Sell	-286,532	Closed	-$2.85M	–	3240
2022 Q3	$2.85M	Hold	286,532	–	–	0.01%	1310
2022 Q2	$2.82M	Hold	286,532	–	–	0.01%	1225
2022 Q1	$2.81M	Hold	286,532	–	–	0.01%	1227
2021 Q4	$2.83M	Hold	286,532	–	–	0.01%	1077
2021 Q3	$2.85M	Hold	286,532	–	–	0.01%	1017
2021 Q2	$2.8M	Hold	286,532	–	–	0.01%	913
2021 Q1	$2.77M	Buy	+286,532	New	+$2.91M	0.01%	920

Other funds holding TLSI

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balyasny Asset Management's TLSI Position: Q2 2025 in Review

Balyasny Asset Management sold out of TriSalus Life Sciences (TLSI) in Q2 2025, closing a stake of 10,804 shares — an estimated $59.6K sold.

Balyasny Asset Management first reported a position in TLSI in Q1 2021 and held it in 8 quarters. The position peaked at $2.85M in Q3 2022. 48 funds tracked by Wall St. Rank hold TLSI as of Q2 2025.

Balyasny Asset Management reported no remaining TriSalus Life Sciences position as of Q2 2025 after selling out during the quarter.
Balyasny Asset Management sold 10,804 TriSalus Life Sciences shares in Q2 2025, an estimated $59.6K.
Balyasny Asset Management first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 8 quarters.
Balyasny Asset Management's TriSalus Life Sciences position peaked at $2.85M in Q3 2022.
48 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.